12:00 AM
 | 
Nov 09, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Voreloxin regulatory update

FDA granted Orphan Drug designation for Sunesis' voreloxin to treat acute myelogenous leukemia (AML). The...

Read the full 53 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >